- Home
- G vs IONS Comparison
G vs IONS Comparison
Compare G & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- G
- IONS
- Stock Information
- Founded
- G 1997
- IONS 1989
- Country
- G Bermuda
- IONS United States
- Employees
- G N/A
- IONS N/A
- Industry
- G Professional Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- G Consumer Discretionary
- IONS Health Care
- Exchange
- G Nasdaq
- IONS Nasdaq
- Market Cap
- G 7.9B
- IONS 6.8B
- IPO Year
- G 2007
- IONS 1991
- Fundamental
- Price
- G $42.11
- IONS $61.10
- Analyst Decision
- G Buy
- IONS Buy
- Analyst Count
- G 7
- IONS 17
- Target Price
- G $50.14
- IONS $67.88
- AVG Volume (30 Days)
- G 1.7M
- IONS 3.3M
- Earning Date
- G 11-06-2025
- IONS 11-05-2025
- Dividend Yield
- G 1.61%
- IONS N/A
- EPS Growth
- G N/A
- IONS N/A
- EPS
- G 3.01
- IONS N/A
- Revenue
- G $4,929,034,000.00
- IONS $944,050,000.00
- Revenue This Year
- G $7.49
- IONS $24.30
- Revenue Next Year
- G $6.69
- IONS $7.39
- P/E Ratio
- G $14.01
- IONS N/A
- Revenue Growth
- G 7.40
- IONS 16.05
- 52 Week Low
- G $37.82
- IONS $23.95
- 52 Week High
- G $56.76
- IONS $64.72
- Technical
- Relative Strength Index (RSI)
- G 34.54
- IONS 72.08
- Support Level
- G $42.67
- IONS $62.79
- Resistance Level
- G $45.65
- IONS $64.61
- Average True Range (ATR)
- G 0.81
- IONS 2.40
- MACD
- G -0.32
- IONS 1.04
- Stochastic Oscillator
- G 0.83
- IONS 84.27
About G Genpact Limited
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.